Your Web News in One Place

Help Webnuz

Referal links:

Sign up for GreenGeeks web hosting
October 6, 2017 05:23 pm GMT

Roivant looks to quickly turn the page, starting with a Phase 3 win

A new hormonal therapy designed to treat uterine fibroids called relugolix has finished a Phase 3 study in Japan, and the results are positive. That’s welcome news for a SoftBank-backed company based in Basel, Switzerland calledRoivant Sciences that’s separately dealing with much lousier news. Read More

Original Link: http://feedproxy.google.com/~r/Techcrunch/~3/9sGKy0O0WRI/

Share this article:    Share on Facebook
View Full Article

Techcrunch

TechCrunch is a leading technology blog, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.

More About this Source Visit Techcrunch